Improving Therapy Outcomes in Relapsed/Refractory Hodgkin Lymphoma

Program Objectives

Brentuximab Vedotin in Hodgkin Lymphoma

Brentuximab Vedotin in Patients With R/R HL

Brentuximab Vedotin: Adverse Events

Nivolumab in Relapsed/Refractory HL

Pembrolizumab in Relapsed/Refractory HL

Checkpoint Inhibitors: Adverse Events

AETHERA Study: Brentuximab as Consolidation Therapy After ASCT

Ongoing Trials with Brentuximab Vedotin and Checkpoint Inhibitors in HL

Educating and Communicating With Patient With HL

Salvage Therapy With Brentuximab Followed By Chemotherapy

Brentuximab + AVD vs ABVD in Advanced Stage HL

Survivorship in Patients With HL

Encouraging Shared Decision Making With Patients

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)